A new type of treatment could double the chances of survival for some patients suffering from the most common type of lung cancer, according to scientists. Drug company Roche has been carrying out tests on an immunotherapy treatment, with early results suggesting it could be a better option than chemotherapy for those with non-small cell lung cancer.